


The present invention relates to compounds of the formula I,





They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (Fxa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their

use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.


Please replace the paragraph at page 2, line 33, to page 3, line 1, of the originally filed application, as amended in Paper No. 11 on page 2, line 33 to page 3, line 2, with the following amended paragraph:

Thus, the present invention relates to compounds of the formula I,




wherein $C_{\alpha 1}$ and $C_{\alpha 2}$ are independently selected from -CH- and -C-.

wherein R_{20} is selected from C_3 alkyl wherein at least one carbon is replaced with nitrogen, sulfur, or oxygen, wherein each carbon or heteroatom is unsubstituted or mono-, or disubstituted independently of one another by R^1 , C_3 alkenyl wherein each carbon is unsubstituted or mono-, or disubstituted independently of one another by R^1 , and C_3 alkenyl wherein at least one carbon is replaced with nitrogen, sulfur, or oxygen, wherein each carbon or heteroatom is unsubstituted or mono-, or disubstituted



independently of one another by R^1 , and the ring comprising
selected from phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R^1 , and pyridyl, wherein pyridyl is unsubstituted or
mono-, di- or trisubstituted independently of one another by R^1 :


wherein R_{20} is selected from C_3 alkyl wherein at least one carbon is replaced with
nitrogen, sulfur, or oxygen, wherein each carbon or heteroatom is unsubstituted or
mono-, or disubstituted independently of one another by R^1 , C_3 alkenyl wherein each
carbon is unsubstituted or mono-, or disubstituted independently of one another by R^1 ,
and C_3 alkenyl wherein at least one carbon is replaced with nitrogen, sulfur, or oxygen,
wherein each carbon or heteroatom is unsubstituted or mono-, or disubstituted




independently of one another by R^1 , and the ring comprising
selected from a 6-membered carbocyclic aryl group, wherein said 6-membered
carbocyclic group is unsubstituted or mono-, di- or trisubstituted independently of one
another by R^1 , and a 6-membered heterocyclic group (Het), containing one or more
heteroatoms as ring heteroatoms, such as nitrogen, sulfur or oxygen, wherein said Het
group is unsubstituted or mono-, di- or trisubstituted independently of one another by
 R^1 :

wherein R_{20} is selected from C_4 - C_7 alkyl comprising a ring wherein at least one
carbon is replaced with nitrogen, sulfur, or oxygen, wherein each carbon or heteroatom

is unsubstituted or mono-, or disubstituted independently of one another by R¹, C₄-C₇-alkenyl comprising a ring wherein each carbon or heteroatom is unsubstituted or mono-, or disubstituted independently of one another by R¹, and C₄-C₇ alkenyl comprising a ring wherein at least one carbon is replaced with nitrogen, sulfur, or oxygen, wherein each carbon or heteroatom is unsubstituted or mono-, or disubstituted independently of



one another by R¹, and the ring comprising  is selected from a bicyclic 7- or 10-membered carbocyclic aryl group, wherein said 7- to 10-membered carbocyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and a bicyclic 7- to 10-membered heterocyclic group (Het), containing one or more heteroatoms as ring heteroatoms, such as nitrogen, sulfur or oxygen, wherein said Het group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹;

Please delete the paragraph at page 4, lines 1-12 of the originally filed application, as amended in Paper No. 11 on page 4, lines 1-2.